Lifecore Biomedical, Inc. (LFCR) Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR). Investors who purchased Lifecore securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/LFCR.

Investigation Details:

On March 20, 2024, Lifecore announced that its Board of Directors had concluded its review of strategic alternatives, in which it “unanimously concluded that the best way to maximize value for stockholders at this time is to continue executing on the Company’s standalone strategic plan.” Lifecore also announced a new CEO. Following this news, Lifecore stock dropped over 30% that same day.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Lifecore securities, you can assist this investigation by visiting the firm’s site: bgandg.com/LFCR. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328166480/en/

The Lifecore Biomedical Stock at the time of publication of the news with a raise of +0,42 % to 4,76USD on Tradegate stock exchange (27. März 2024, 22:26 Uhr).